This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Freidank, H. M.
Right arrow Articles by Wiedmann-Al-Ahmad, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freidank, H. M.
Right arrow Articles by Wiedmann-Al-Ahmad, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1999, p. 1808-1810, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Susceptibilities of Chlamydia pneumoniae Isolates from German Patients and Synergistic Activity of Antibiotic Combinations

Heike M. Freidank,* Philipp Losch, Heike Vögele, and Margit Wiedmann-Al-Ahmad

Department of Bacteriology, Institute for Medical Microbiology and Hygiene, University of Freiburg, D-79104 Freiburg, Germany

Received 23 November 1998/Returned for modification 8 March 1999/Accepted 10 May 1999

The susceptibilities of six Chlamydia pneumoniae type strains and of six German patient isolates to erythromycin, azithromycin, roxithromycin, clarithromycin, doxycycline, ofloxacin, and rifampin were investigated. MICs and minimal chlamydicidal concentrations were all within the ranges reported previously. Combinations of azithromycin with either ofloxacin, doxycycline, or rifampin, as well as combinations of three antibiotics (rifampin, azithromycin, and ofloxacin or doxycycline), showed synergistic activity against C. pneumoniae.

* Corresponding author. Mailing address: Department of Bacteriology, Institute for Medical Microbiology and Hygiene, University of Freiburg, Hermann-Herder-Str. 11, D-79104 Freiburg, Germany. Phone: 049-761 203 6540. Fax: 049-761 203 6562. E-mail: freidank{at}sun11.ukl.uni-freiburg.de.

Antimicrobial Agents and Chemotherapy, July 1999, p. 1808-1810, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Volanen, I., Kallio, K., Saarinen, M., Jarvisalo, M. J., Vainionpaa, R., Ronnemaa, T., Viikari, J., Marniemi, J., Simell, O., Raitakari, O. T. (2008). Arterial Intima-Media Thickness in 13-Year-Old Adolescents and Previous Antichlamydial Antimicrobial Use: A Retrospective Follow-up Study. Pediatrics 122: e675-e681 [Abstract] [Full Text]  
  • Kutlin, A., Kohlhoff, S., Roblin, P., Hammerschlag, M. R., Riska, P. (2005). Emergence of Resistance to Rifampin and Rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. Antimicrob. Agents Chemother. 49: 903-907 [Abstract] [Full Text]  
  • Roblin, P. M., Reznik, T., Kutlin, A., Hammerschlag, M. R. (2003). In Vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 47: 1135-1136 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»